Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2018/04/08 01:04:31」(JST)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 統合失調症に対する薬物療法：副作用マネージメント pharmacotherapy for schizophrenia side effect management
2. 第一世代（定型）抗精神病剤中毒 first generation typical antipsychotic medication poisoning
3. 第二世代抗精神病薬：薬理学、用法および副作用 second generation antipsychotic medications pharmacology administration and side effects
4. 遅発性ジスキネジア：予防および治療 tardive dyskinesia prevention and treatment
5. 小児の双極性障害：治療法の選択に関する概要 pediatric bipolar disorder overview of choosing treatment

Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.

Tybura P1, Trześniowska-Drukała B1, Bienkowski P2, Beszlej A3, Frydecka D3, Mierzejewski P2, Samochowiec A4, Grzywacz A1, Samochowiec J5.
Psychiatry research.Psychiatry Res.2014 Oct 30;219(2):261-7. doi: 10.1016/j.psychres.2014.05.039. Epub 2014 Jun 2.
The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in paranoid schizophrenia patients. The second aim of the study was to compare the intensity of the
PMID 24930580

Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia.

Tian L1, Tan Y2, Chen D2, Lv M2, Tan S2, Soares JC3, Zhang XY4.
Progress in neuro-psychopharmacology & biological psychiatry.Prog Neuropsychopharmacol Biol Psychiatry.2014 Oct 3;54:259-64. doi: 10.1016/j.pnpbp.2014.06.012. Epub 2014 Jul 2.
BACKGROUND: Mounting evidences have demonstrated the association of altered immune factors with neurodevelopmental and pathological progression of schizophrenia. However, whether immune factors play any role in the pathogenesis of tardive dyskinesia (TD) has been underexplored. To our best knowledge
PMID 24995685

Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study.

Uchida H1, Suzuki T2, Graff-Guerrero A3, Mulsant BH4, Pollock BG4, Arenovich T5, Rajji TK3, Mamo DC6.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.Am J Geriatr Psychiatry.2014 Oct;22(10):1007-16. doi: 10.1016/j.jagp.2013.01.045. Epub 2013 Feb 6.
OBJECTIVE: In younger patients with schizophrenia, positron emission tomography (PET) studies have identified a therapeutic window of striatal dopamine D2/3 receptor occupancy of 65%-80%. This type of empirical information is not available in late life. Our primary aim was to assess the effect of ch
PMID 25217025

Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database